Composite material consisting of microporous beta-TCP ceramic and alginate-dialdehyde-gelatin for controlled dual release of clindamycin and bone morphogenetic protein 2
© 2023. The Author(s)..
The aim of this study was to produce a composite of microporous β-TCP filled with alginate-gelatin crosslinked hydrogel, clindamycin and bone morphogenetic protein (BMP-2) to prolong the drug-release behaviour for up to 28 days. The most promising alginate-di-aldehyde(ADA)-gelatin gel for drug release from microcapsules was used to fill microporous β-TCP ceramics under directional flow in a special loading chamber. Dual release of clindamycin and BMP-2 was measured on days 1, 2, 3, 6, 9, 14, 21 and 28 by high performance liquid chromatography (HPLC) and enzyme-linked immunosorbent assay (ELISA). After release, the microbial efficacy of the clindamycin was checked and the biocompatibility of the composite was tested in cell culture. Clindamycin and the model substance FITC-protein A were released from microcapsules over 28 days. The clindamycin burst release was 43 ± 1%. For the loaded ceramics, a clindamycin release above the minimal inhibitory concentration (MIC) until day 9 and a burst release of 90.56 ± 2.96% were detected. BMP-2 was released from the loaded ceramics in low concentrations over 28 days. The release of active substances from β-TCP and hydrogel have already been extensively studied. Directional flow loading is a special procedure in which the ceramic could act as a stabilizer in the bone and, as a biodegradable system, enables a single-stage surgical procedure. Whether ADA-gelatin gel is suitable for this procedure as a more biodegradable alternative to pure alginate or whether a dual release is possible in this composite has not yet been investigated.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:34 |
|---|---|
| Enthalten in: |
Journal of materials science. Materials in medicine - 34(2023), 8 vom: 27. Juli, Seite 39 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ritschl, Lucas [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
3U02EL437C |
|---|
| Anmerkungen: |
Date Completed 31.07.2023 Date Revised 23.08.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s10856-023-06743-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359984614 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359984614 | ||
| 003 | DE-627 | ||
| 005 | 20231226082034.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10856-023-06743-1 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1199.xml |
| 035 | |a (DE-627)NLM359984614 | ||
| 035 | |a (NLM)37498466 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ritschl, Lucas |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Composite material consisting of microporous beta-TCP ceramic and alginate-dialdehyde-gelatin for controlled dual release of clindamycin and bone morphogenetic protein 2 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.07.2023 | ||
| 500 | |a Date Revised 23.08.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a The aim of this study was to produce a composite of microporous β-TCP filled with alginate-gelatin crosslinked hydrogel, clindamycin and bone morphogenetic protein (BMP-2) to prolong the drug-release behaviour for up to 28 days. The most promising alginate-di-aldehyde(ADA)-gelatin gel for drug release from microcapsules was used to fill microporous β-TCP ceramics under directional flow in a special loading chamber. Dual release of clindamycin and BMP-2 was measured on days 1, 2, 3, 6, 9, 14, 21 and 28 by high performance liquid chromatography (HPLC) and enzyme-linked immunosorbent assay (ELISA). After release, the microbial efficacy of the clindamycin was checked and the biocompatibility of the composite was tested in cell culture. Clindamycin and the model substance FITC-protein A were released from microcapsules over 28 days. The clindamycin burst release was 43 ± 1%. For the loaded ceramics, a clindamycin release above the minimal inhibitory concentration (MIC) until day 9 and a burst release of 90.56 ± 2.96% were detected. BMP-2 was released from the loaded ceramics in low concentrations over 28 days. The release of active substances from β-TCP and hydrogel have already been extensively studied. Directional flow loading is a special procedure in which the ceramic could act as a stabilizer in the bone and, as a biodegradable system, enables a single-stage surgical procedure. Whether ADA-gelatin gel is suitable for this procedure as a more biodegradable alternative to pure alginate or whether a dual release is possible in this composite has not yet been investigated | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Alginates |2 NLM | |
| 650 | 7 | |a beta-tricalcium phosphate |2 NLM | |
| 650 | 7 | |a Bone Morphogenetic Protein 2 |2 NLM | |
| 650 | 7 | |a Capsules |2 NLM | |
| 650 | 7 | |a Clindamycin |2 NLM | |
| 650 | 7 | |a 3U02EL437C |2 NLM | |
| 650 | 7 | |a Gelatin |2 NLM | |
| 650 | 7 | |a 9000-70-8 |2 NLM | |
| 650 | 7 | |a Hydrogels |2 NLM | |
| 700 | 1 | |a Schilling, Pia |e verfasserin |4 aut | |
| 700 | 1 | |a Wittmer, Annette |e verfasserin |4 aut | |
| 700 | 1 | |a Bohner, Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Bernstein, Anke |e verfasserin |4 aut | |
| 700 | 1 | |a Schmal, Hagen |e verfasserin |4 aut | |
| 700 | 1 | |a Seidenstuecker, Michael |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of materials science. Materials in medicine |d 1991 |g 34(2023), 8 vom: 27. Juli, Seite 39 |w (DE-627)NLM089783999 |x 1573-4838 |7 nnns |
| 773 | 1 | 8 | |g volume:34 |g year:2023 |g number:8 |g day:27 |g month:07 |g pages:39 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10856-023-06743-1 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 34 |j 2023 |e 8 |b 27 |c 07 |h 39 | ||